AHA News: Eating Foods That Promote Inflammation May Worsen Heart Failure | Health News


By American Heart Association News, HealthDay Reporter

(HealthDay)

MONDAY, Nov. 30, 2020 (American Heart Association News) — People with heart failure who eat a diet high in foods that cause inflammation are twice as likely to end up in the hospital or die as those who eat foods known to reduce inflammation, new research shows.

“If people with heart failure can reduce the amount of pro-inflammatory foods that they eat, it might help with their survival,” said lead researcher JungHee Kang, a nursing research assistant and PhD student at the University of Kentucky in Lexington.

Diet has been shown to play a role in regulating inflammation, which is associated with many chronic illnesses, including heart disease. Diets high in foods such as red meat, refined grains and high-fat dairy products have been shown to increase inflammation, while foods such as olive oil, whole grains, and fruits and vegetables have been

Read More

Study: Heart failure risk in older women increases with more sedentary time


Nov. 24 (UPI) — Older women have a greater risk of heart failure if they spend more time sitting than those who sit less — even if they have a regular fitness routine — a new study found.

Researchers analyzed records for nearly 80,100 postmenopausal women, who were 63 years of age on average, from the Women’s Health Initiative Observational Study, for the study published Tuesday.

The initiative allowed women to self-report time spent sitting or lying down in waking hours and or moving.

Women who spent less than 6.5 hours a day sitting or lying down in waking hours, had 15% less risk of heart failure hospitalization than women reporting up to 9.5 sedentary hours, and 42% less risk than women reporting more than 9.5 hours sedentary hours, the data showed.

Analysts gathered data from an average of nine years of follow-up on the women, during which 1,402 women

Read More

Pumping Iron: IV Supplement Helps Heart Failure Patients


Heart failure patients who are diagnosed with iron deficiency appear to avoid return trips to the hospital if they are treated with intravenous ferric carboxymaltose to replete iron stores, researchers reported at the virtual 2020 scientific sessions of the American Heart Association.

In the Affirm-AHF trial, patients treated with ferric carboxymaltose had a relative risk reduction of 21% in the primary composite endpoint of hospitalization and cardiovascular death when compared with patients who received placebo (P=0.059), reported Piotr Ponikowski, MD, PhD, of Wroclaw Medical University in Poland.

The result was primarily driven by a reduction in hospitalizations – which achieved statistical significance with a relative risk reduction of 26% (P=0.013). This result was achieved with only one or two injections in 80% of the patients in the ferric carboxymaltose group, Ponikowski said at an AHA press conference.

He said that the COVID-19 epidemic had an impact

Read More

Relief, with Partner NeuroRx, Announces Enrollment of 150 Patients in Phase 2b/3 Trial of RLF-100(TM) for Critical COVID-19 with Respiratory Failure


  • Observations of rapid recovery on chest x-rays noted and no drug-related Serious Adverse Events reported

  • Relief also reports exercise of 500 million warrants by main shareholder GEM

GENEVA, SWITZERLAND / ACCESSWIRE / November 13, 2020 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) (“Relief” or the “Company“) with its partner NeuroRx, Inc., announced that as of today, 150 patients (out of a targeted enrollment of 165) have been enrolled in the ongoing phase 2b/3 trial of RLF-100(TM) (aviptadil) for treating respiratory failure in patients with critical COVID-19. Respiratory failure is defined, according to FDA guidance, as the need for intensive care with mechanical ventilation, non-invasive ventilation, or high-flow nasal oxygen in order to sustain adequate levels of blood oxygen. So far, no drug-related serious adverse events have been reported.

There is currently no FDA-approved drug that has shown efficacy in patients who are already in the Intensive Care

Read More

The government’s coronavirus response is now officially a failure by its own measure


As cases mounted and localities began shutting down economic activity to contain the virus’s spread, the White House coronavirus task force suddenly took a new approach. It rolled out recommendations aimed at curtailing the rampant spread of the virus, citing data suggesting that, without intervention, between 1.5 million and 2.2 million people might die. With an effort at intervention, the toll might be somewhere from 100,000 to 240,000 deaths.

For a while, this was Trump’s benchmark for success.

“Models predicted between 1.5 million and 2.2 million U.S. deaths — if there was no mitigation, it could have even been higher than that — and between 100,000 and 240,000 deaths with mitigation,” he said in mid-April. “It’s looking like we will come far under even these lowest numbers.”

Even five months later, he was making similar claims. At a briefing in mid-September, he showed the same graph.

“This was our prediction

Read More

All weight loss isn’t equal for reducing heart failure risk


All weight loss isn't equal for reducing heart failure risk
Ambarish Pandey, M.D. Credit: UT Southwestern Medical Center

Reducing the level of body fat and waist size are linked to a lower risk of heart failure in patients with type 2 diabetes, a study led by UT Southwestern researchers indicates. The findings, reported today in Circulation, suggest that all weight loss isn’t equal when it comes to mitigating the risk of heart disease.

The burden of diabetes is increasing, with an estimated 700 million adults worldwide predicted to have this disease by 2045. The vast majority of cases are type 2 diabetes, characterized by insulin resistance, an inability for cells to respond to insulin. Type 2 diabetes doubles the risk of cardiovascular events such as heart failure and heart attacks.

Being overweight and obese are strong risk factors for both type 2 diabetes and heart disease, and patients are often counseled to lose weight to reduce the likelihood of

Read More